Alice Blue - 20 years of trust
    • ANT APP
    • ANT WEB
    • 1LyAlgos
    • 1lyOptions
    • TradingView
    • MTF
    • Insurance
    • IPO
    • Stocks
    • Mutual Funds
    • US Stocks
  • Partner with us
  • Trade School
  • Pricing

    • Pricing

    About Us

    • About Us

    Calculator

    • Calculators
    • Brokerage Calculator
    • MTF Calculator

    Resources

    • Blog
    • Webinars
    • Videos (YouTube)

    Updates

    • News
    • Trading Holidays
    • Cares
    • Media Coverage
    • Disclosures

    Support

    • Support
    • Refer & Earn
    CommunityCareers
Login

    Start Investing in Stocks₹0 Account Opening

    +91
    Top Gainers Today52 Weeks High StocksHistorical Returns StocksShare Market TodayTop Losers TodayStocks Market NewsPC JewellerVodafone IdeaTata Gold ETFNip. India GoldNippon I SilverYes BankTata Silver ETFHMA Agro Inds.V2 RetailUgro CapitalHDFC BankDSP Gold ETFICICI Gold ETFZerodha Gold ETFSuzlon EnergyTata SteelCanara BankMoneyviewSagility
    NIFTY 50NIFTY Midcap 100NIFTY 100NIFTY RealtySENSEXNIFTY AutoNIFTY PSU BankNIFTY FMCGNIFTY BANKNIFTY MIDCAP 150BSE EnergyNIFTY PharmaBSE 100 LargeCap TMCNIFTY NEXT 50NIFTY MetalBSE 500 QUALITY 50
    Options Nifty 50Options BANK NIFTYOptions MIDCPNIFTYOptions FINNIFTYFutures Highest OIFutures OI GainersFutures OI LosersFutures Top Traded
    Debt Mutual FundsBest Debt Mutual fundsBest Equity Mutual fundsBest Hybrid Mutual fundsBest MidCap Mutual fundsBest Multicap Mutual fundsBest Large Cap Mutual fundsBest Small Cap Mutual fundsBest ELSS Mutual fundsBest Contra Mutual fundsBest Value Mutual fundsBest Arbitrage Mutual fundsBest Dividend Yield Mutual fundBest Aggressive Mutual fundsBest Conservative Mutual funds
    SIP CalculatorBrokerage CalculatorHome Loan EMI CalculatorLumpsum CalculatorMargin CalculatorFD CalculatorSWP CalculatorMF CalculatorEMI CalculatorStep-Up SIP CalculatorPPF Calculator
    What Is IPO?Open IPOsUpcoming IPOsHow to Apply for an IPOWhat is Grey Market Premium?
    Shares
    Top Gainers Today52 Weeks High StocksHistorical Returns StocksShare Market TodayTop Losers TodayStocks Market NewsPC JewellerVodafone IdeaTata Gold ETFNip. India GoldNippon I SilverYes BankTata Silver ETFHMA Agro Inds.V2 RetailUgro CapitalHDFC BankDSP Gold ETFICICI Gold ETFZerodha Gold ETFSuzlon EnergyTata SteelCanara BankMoneyviewSagility
    Indices
    NIFTY 50NIFTY Midcap 100NIFTY 100NIFTY RealtySENSEXNIFTY AutoNIFTY PSU BankNIFTY FMCGNIFTY BANKNIFTY MIDCAP 150BSE EnergyNIFTY PharmaBSE 100 LargeCap TMCNIFTY NEXT 50NIFTY MetalBSE 500 QUALITY 50
    F&O
    Options Nifty 50Options BANK NIFTYOptions MIDCPNIFTYOptions FINNIFTYFutures Highest OIFutures OI GainersFutures OI LosersFutures Top Traded
    Mutual Funds
    Debt Mutual FundsBest Debt Mutual fundsBest Equity Mutual fundsBest Hybrid Mutual fundsBest MidCap Mutual fundsBest Multicap Mutual fundsBest Large Cap Mutual fundsBest Small Cap Mutual fundsBest ELSS Mutual fundsBest Contra Mutual fundsBest Value Mutual fundsBest Arbitrage Mutual fundsBest Dividend Yield Mutual fundBest Aggressive Mutual fundsBest Conservative Mutual funds
    Calculators
    SIP CalculatorBrokerage CalculatorHome Loan EMI CalculatorLumpsum CalculatorMargin CalculatorFD CalculatorSWP CalculatorMF CalculatorEMI CalculatorStep-Up SIP CalculatorPPF Calculator
    IPO
    What Is IPO?Open IPOsUpcoming IPOsHow to Apply for an IPOWhat is Grey Market Premium?

    Company
    • About Us
    • Work with Us
    • Terms and Conditions
    • EKYC Guidelines
    • Contact Us
    • Cares
    Apps and Products
    • ANT APP
    • ANT WEB
    • 1LYOptions
    • Trade School
    • TradingView
    • 1LyAlgos
    • US Stocks
    Calculators
    • Calculators
    • SIP Calculator
    • Mutual Funds Return Calculator
    • Brokerage Calculator
    • RMS Live Updates
    • Term Coverage Calculator
    Important Links
    • Pricing
    • KYC Tracker
    • Market News
    • Global Indices
    • Gold Rate
    • Silver Rate
    • Trading Holidays

    Alice Blue
    3rd Floor, M.R.B.Arcade, No. 153/2,
    Bagalur Main Rd, Dwarka Nagar,
    Yelahanka, Bengaluru, Karnataka
    560063
    FacebookLinkedInX (Twitter)YouTubeInstagramWhatsapp

    ISO 27001:2022 Alice Blue is Certified Information Security Management System (ISMS)

    ISO 22301:2019 Alice Blue is Certified Business Continuity Management System (BCMS)

    DownloadsCircularsBank DetailsLearn
    Trade on TradingViewGet it on Google PlayDownload on the App Store

    Attention Investors!
    Prevent unauthorized transactions in your account update your mobile number/ email Id with your Stock Broker. Receive information of your transactions directly from Exchange on your mobile / email id at the end of the day.Prevent unauthorized transactions in your account update your mobile number/ email Id with your Stock Broker. Receive information of your transactions directly from Exchange on your mobile / email id at the end of the day.

    Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from the depository on your email id and/or mobile number to create a pledge. Pay 20% upfront margin of the transaction early to trade in the cash market segment. Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020, and NSE/INSP/45534 dated August 31, 2020, and other guidelines issued from time to time in this regard. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

    Corporate Office: No. 153/2, 3rd Floor, M.R.B.Arcade, Bagalur Main Road, Dwaraka Nagar, Yelahanka, Bengaluru – 560 063, Karnataka.
    Registered Office: Old No.56/2 ,New No.58, LIC Nagar, Vinayagar Kovil Street, Erode -8,Tamil Nadu– 638002.
    Alice Blue Financial Services (P) Ltd : NSE EQ | NSE FO | NSE CDS-90112 SEBI REG : INZ000156038
    Alice Blue Financial Services (P) Ltd : BSE EQ | BSE FO | BSE CD-6670 SEBI REG : INZ000156038
    Alice Blue Financial Services (P) Ltd : CDSL DP ID 12085300 DP SEBI REG : IN-DP-364-2018
    Alice Blue Financial Services (P) Ltd : MCX-56710 SEBI REG : INZ000156038

    COMPLIANCE OFFICER: SARAVANAN R | Mobile No: +91 91872 10670 | Email:[email protected]

    We hereby declare that we are doing PRO trading

    Procedure to file a complaint on SEBI SCORES / SMART ODR : Register on SEBI SCORES 2.0 / SMART ODR. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances

    Click on the provided link to learn about the process for submitting a complaint on the ODR platform for resolving investor grievances. ODR Circular

    Investment in securities markets are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit.

    For queries regarding account opening or activation, email to accountactivation@aliceblueindia.com and for fund updates, email to funds@aliceblueindia.com

    Disclaimer: Attention investors:1) Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors. 2) Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. 3) Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. 4) For demat and trading account closure with AliceBlue, kindly visit https://aliceblueonline.com/support/closure-freezing-reactivation or “ANT APPLICATION” under your profile and click on Settings -> Account Closure section -> Initiate account closure.

    No need to issue cheques by investors while subscribing to an IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in the investor’s account.

    Investors are requested to note that Alice Blue Financial Services Private Limited is permitted to receive money from investor through designated bank accounts only named as Up streaming Client Nodal Bank Account (USCNBA). Alice Blue Financial Services Private Limited is also required to disclose these USCNB accounts to Stock Exchange. Hence, you are requested to use following USCNB accounts only for the purpose of dealings in your trading account with us. The details of these USCNB accounts are also displayed by Stock Exchanges on their website under “Know/ Locate your Stock Broker. Bank Details (Valid UPI FAQ).

    DND PolicyInvestor CharterLegal DocumentationPrivacy policyFeedbackAnnual ReturnsAdvisory for InvestorsE-votingMandatory Member Details

    Performance

    Historical price movement and trading activity

    Trading Data

    Today's High

    3872

    Today's Low

    3816

    Open

    3850.3

    Previous Close

    3856

    Volume

    13808

    Total Traded Value High

    53118772.6

    Technicals

    Price-based indicators and levels

    Indicators

    IndicatorValueSignal
    Relative Strength Index (RSI)+50.14Neutral
    MACD-11.67Bearish

    Support and Resistance Levels

    R33931.77
    R23895.83
    R13873.07
    S13814.37
    S23778.43
    S33755.67

    Moving Averages

    PeriodSMAEMA
    20D Moving Average3809.713838.90
    50D Moving Average3874.483960.81
    200D Moving Average4521.764415.71
    Pfizer Ltd

    Pfizer Ltd

    NSE: PFIZER | BSE: 500680
    ₹3856+5.70 (0.15%)
    BuySell

    News

    Volumes jump at Pfizer Ltd counter

    8 Sept 2026

    Pfizer Ltd witnessed volume of 1.42 lakh shares by 14:24 IST on NSE, a 7.67 times surge over two-week average daily volume of 18557 shares

    PCBL Chemical Ltd, Jubilant Pharmova Ltd, Piramal Pharma Ltd, OneSource Specialty Pharma Ltd are among the other stocks to see a surge in volumes on NSE today, 08 September 2026. Pfizer Ltd witnessed volume of 1.42 lakh shares by 14:24 IST on NSE, a 7.67 times surge over two-week average daily volume of 18557 shares. The stock dropped 5.73% to Rs.4,333.00. Volumes stood at 17548 shares in the last session. PCBL Chemical Ltd witnessed volume of 50.95 lakh shares by 14:24 IST on NSE, a 7.15 times surge over two-week average daily volume of 7.13 lakh shares. The stock increased 2.41% to Rs.325.10. Volumes stood at 11.25 lakh shares in the last session. Jubilant Pharmova Ltd witnessed volume of 12.33 lakh shares by 14:24 IST on NSE, a 5.93 times surge over two-week average daily volume of 2.08 lakh shares. The stock increased 4.64% to Rs.994.40. Volumes stood at 3.17 lakh shares in the last session. Piramal Pharma Ltd clocked volume of 196.28 lakh shares by 14:24 IST on NSE, a 5.31 times surge over two-week average daily volume of 36.93 lakh shares. The stock gained 2.69% to Rs.225.57. Volumes stood at 64.07 lakh shares in the last session. OneSource Specialty Pharma Ltd recorded volume of 6.53 lakh shares by 14:24 IST on NSE, a 5.09 times surge over two-week average daily volume of 1.28 lakh shares. The stock gained 1.27% to Rs.1,572.00. Volumes stood at 1.4 lakh shares in the last session.

    Trade now

    Overview

    Pharmaceuticals - MultinationalNSE / BSE

    Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories. It has its own manufacturing facility at Goa and Thane. It has the distinction of being the first pharmaceutical company in India to start clinical research. The Company sells products in nearly 185 countries having 43 manufacturing sites globally. Their 6 primary therapeutic areas includes, Internal Medicine, Oncology, Hospital, Vaccines, Inflammation & Immunology and Rare Diseases. Pfizer Limited came to the Indian market on 21st November, 1950 through a company, 'Dumex Limited'. The first production facility was set up at Darukhanna in Mumbai, where products like Protinex and Isonex (isoniazid - an anti -TB drug) were manufactured. Subsequently, this plant also produced Becosules and Corex. In 1960, Pfizer established a large and modern plant at Thane, near Mumbai, which housed manufacturing, quality control and product research facilities. This plant won a number of national safety awards. In November of the year 1965, the Company had entered into a licence agreement with Pfizer Corporation continuing the royalty-free licence granted to it for the use of Pfizer processes, technical know-how, etc., relating to the manufacture of existing products in the pharmaceutical, veterinary and agricultural fields and giving the Company the right to obtain from Pfizer Corporation by Mutual agreement, technical know-how and other assistance relating to the manufacture of new items. A large research and development laboratory of the company at Thane was commissioned in the year 1969. As of 4th March of the year 1977, the company's status was changed as a public limited company. Piroxicam, a major anti-artharitic drug, was launched in India in the last quarter of the year 1989 under the brand name of DOLONEX. The former subsidiary Dumex Ltd was amalgamated with the company effect from 1st April of the year 1992 and also during the same year, the pharmaceuticals division introduced Dolmex' intramuscular injection. Development Operations (Dev Ops) India, formerly a part of the Clinical Research Division, was established in 1995. The operations started with the hiring of a statistician in 1995. Pfizer had acquired the animal healthcare operations of SmithKline Beecham in the year 1996. The pace of work of Clinical Research Division was picked up in 1998 and this was followed by a substantial growth in terms of activities and resources, especially in data management. A dedicated Informatics group of the company for all technical and applications support has been available since 1997. The Company closed down its manufacturing plant at Ankleshwar with effect from 31st July of the year 1999. During the year 2000, PL made tie-up with Shantha Biotechnics for parallel marketing of its products. Express Pharma Biz Award came to company's hands in the year 2002 for overall performance. The operational merger between the company and Parke-Davis had been completed in the year 2002. A year after, in 2003, Pfizer had initiated the global implementation of 'Clinicopia Labelling and Clinicopia Supply Chain' a part of inferno's Clinical Trials management suite. In mid 2003, the Mumbai group was aligned under Dev Ops Europe to emphasize its focus on operations and facilitate more interactions and project engagements from all sites. In the year 2004, PL had entered into an agreement with Sanofi Synthelabo (India) Ltd for co-promotion of its product, Daxid. The Company's seven key brands (Corex, Becosules, Magnex, Dolonex, Gelusil, Minipress XL and Benadryl) had listed among the Top-100 Industry brands, in the year 2005. Viagra was the first global brand launched in December of the year 2005, followed by Caduet (a combination of atorvastatin and amlodipine for treatment of patients with dyslipidemia and hypertension) and LYRICA (pregabalin, for treatment of neuropathic pain), both of which launched in the first quarter of 2006. The Company bagged Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera. The global divesture of the OTC business to Johnson & Johnson in December 2006 and Pfizer, won a US Supreme Court appeal in April of the year 2007 that aimed to open the company's Lipitor cholesterol pill, the most widely prescribed drug in the world, to generic competition, also in end of the year 2007, the company had transferred its exclusive license to Johnson & Johnson for a total consideration of Rs 2,148.51 million. Pfizer had launched Champix, a non-nicotine smoking cessation prescription drug during February of the year 2008. On 12 April 2009, Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, announced that it will make a tender offer to acquire a 33.77% stake in Pfizer Limited from public shareholders at a price of Rs. 675 per share. Successful completion of this offer, assuming full acceptance, would raise the indirect stake of Pfizer Inc in Pfizer Limited to 75% from the current level of 41.23%. The offer will represent a total value of up to Rs 680 crore, or approximately USD 136 million. The Board of Directors of Pfizer Ltd at its meeting held on 26 September 2009 approved the Scheme of Amalgamation of Duchem Laboratories Ltd (wholly owned subsidiary of Pfizer Ltd) and Pfizer Ltd. The Scheme is proposed to be effective 1 December 2008. The Transferor Company being the wholly owned subsidiary of Pfizer Ltd, no consideration shall be payable to the Transferor Company or its shareholders pursuant to the Amalgamation and the shares held by Pfizer Ltd and its nominees in the Transferor Company shall stand cancelled. The Board of Directors of Pfizer Ltd at its meeting held on 6 February 2012 approved the sale of its animal health division by way of a slump sale to its wholly owned subsidiary (being incorporated) in consideration of approximately Rs 440 crore, subject to adjustment for working capital, to be paid by the wholly owned subsidiary (being incorporated) either in cash and/or by issue of shares (at par or premium) on such terms as may be agreed to by the Board of Directors. In July 2011, Pfizer Inc USA., the Ultimate Holding Company of Pfizer Ltd, announced that it was reviewing strategic alternatives for its global animal health business. The Board of Directors of Pfizer Ltd at its meeting held on 8 November 2012 approved the sale of its animal health business to Pfizer Animal Health India Limited, a 100% indirect subsidiary of Pfizer Inc., USA for a consideration of Rs 471.60 crore. Pfizer Ltd issued to all concerned a lock out notice on 1 August 2014 at its plant situated at Thane Belapur Road, K.U. Bazar P.O., Navi Mumbai (the Plant). This said notice for the proposed lock-out has been necessitated on account of several acts, as a result of which the Company is of the belief that it has become impossible for the management to continue with the operations of the Plant in a peaceful and productive manner. The above lock-out notice will have no impact on the business operations of the Company. The Company has in place a robust business continuity plan which will ensure that its medicines are available to the patients at all times.On 1 December 2014, Pfizer Limited announced the completion of the merger with Wyeth Limited. The Scheme of Amalgamation between Wyeth Limited and Pfizer Limited and their respective shareholders and creditors (Scheme) was sanctioned by the Bombay High Court vide its order dated 31 October 2014. As per the provisions of the Scheme, 7 (seven) equity shares of Rs. 10/- (Rupees Ten only) each fully paid up of Pfizer Limited, will be issued for every 10 (ten) equity shares of Rs.10/- (Rupees Ten only) each fully paid up held in Wyeth Limited. The merger places Pfizer Limited among the top 10 pharmaceutical companies in India by market share. Pfizer Inc., USA, through its subsidiaries holds the majority stake in both companies and will continue to remain the majority shareholder with an approximate 63.9% holding in Pfizer Limited, post-merger. Wyeth Ltd. is a market leader in vaccines and women's health. Wyeth has pioneered the introduction of several new therapies in India and was the first to launch hormone replacement therapy and conjugated pneumococcal vaccines for infants and adults. On 15 July 2015, Pfizer Ltd has informed the stock exchanges that the company has intimated the concerned authorities that it intends to effect closure of its plant situated at Thane Belapur Road, K.U. Bazar P.O., Navi Mumbai ('the Plant') with effect from 16 September 2015. The decision to close the Plant is based on an assessment of its long term viability and its ability to achieve the needed production. There has practically been no production activity at this plant since 2013, and the closure will not impact the supply of any of the Company's medicines to patients. On 24 September 2015, Pfizer Ltd informed the stock exchanges that the company has intimated the concerned authorities that it has withdrawn its notice dated 15 July 2015, whereby it had intended to effect closure of its plant situated at Thane Belapur Road, K.U. Bazar P. O., Navi Mumbai ('the Plant'), as the Company has entered into a Business Transfer Agreement to sell the Plant as a going concern to Vidhi Research & Development LLP. On 23 September 2015, Pfizer Ltd had informed the stock exchanges that it had entered into a Business Transfer Agreement (BTA) for the transfer of the Company's business at the Thane Plant as a going concern to Vidhi Research and Development LLP in accordance with the terms of the agreement for a lump sum consideration of Rs 178 crore. On 14 March 2016, Pfizer Ltd. announced that it has discontinued the manufacture and sale of its drug 'Corex' with immediate effect in view of Government of India notification dated 10 March 2016 prohibiting the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect. The above prohibition is likely to have an adverse impact on the revenue and profitability of the company. The company is exploring all available options at its disposal. On the same day, the Delhi High Court granted an interim injunction suspending the operation of the said government notification banning the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup till the next date of hearing. Corex recorded sale of Rs 176 crore for the nine months period ended 31 December 2015. On 13 May 2016, Pfizer Ltd. announced that it has signed an agreement for the sale of four products marketed by its Global Established Products business in India. The brands Neko Soap, Sloans, Ferradol and Waterburys Compound will be divested to Piramal Enterprises Limited, for a consideration of Rs 110 crore, subject to adjustments for inventory on closing. The closure of this transaction is subject to obtaining requisite regulatory approvals and fulfilment of certain conditions by the parties. On 29 November 2016, Pfizer Ltd announced that has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation (Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg) as part of a comprehensive review of its respiratory offerings. The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year. The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex Cough Syrup formulation. Corex Cough Syrup recorded a sale of Rs 244.48 crores for the financial year ended 31 March 2016. On 18 January 2017, Pfizer Limited announced that it has entered into a Delegation of Authority (DoA) with AstraZeneca Pharma India Limited (AstraZeneca), pursuant to which AstraZeneca has granted certain authority to the company to conduct certain activities in India. The said DoA is a result of a global agreement whereby Pfizer Inc. through its affiliates acquired from AstraZeneca PLC (through its affiliates) the development and commercial rights of their late-stage small molecule anti-infectives business. By way of this DoA, the company has been granted the authority, inter alia, to carry out the activities of pricing and reimbursement negotiations, promotional, marketing, tendering, bidding, and distribution in relation the identified injectable antibiotic products. Pursuant to this, Meronem Injection which is currently marketed in India by AstraZeneca is expected to be transitioned to Pfizer Limited. On 31 May 2017, Pfizer Limited (India) informed the stock exchanges that it has entered into an agreement with AstraZeneca AB, Sweden, to acquire the brand 'Neksium' in India for a value of Rs 75 crore. The transaction is subject to completion of requisite clearances. Neksium was launched in India in the year 2006 and has developed strong equity with prescribers as a leading, high quality product in the Anti-Peptic Ulcerant space. Neksium, with the active ingredient Esomeprazole belongs to a class of pharmaceutical preparations called Proton Pump Inhibitors' (PPI) which are used effectively for reducing the acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the Acid Peptic Disorders (APD) spectrum. Neksium (esomeprazole) complements Pfizer Limited's existing product portfolio in the gastrointestinal (GI) therapeutic area. Pfizer Inc., USA had announced on October 10, 2017 that it was considering a review of strategic alternatives for its Global Consumer Healthcare business. Further to this, in December 2018, Pfizer Inc. had announced the formation of a joint venture between Pfizer Inc. and GlaxoSmithKline Plc. to create a premier global consumer healthcare company with robust iconic brands. The Company had been informed by Pfizer Inc. that the brands Anne French and Anacin which are currently marketed by your Company will become a part of the portfolio of the Joint Venture company. In 2019, Enbrel, the first Tumor Necrosis Factor (TNF) inhibitor was launched. It launched Zavicefta drug; in 2021, it launched Gastroesophageal Reflux Disease (GERD) Clinic. The Company on September 30, 2021 entered into a business transfer agreement (BTA) with Mylan Pharmaceuticals Private Limited (Mylan), subsidiary of Viatris Inc to transfer certain primarily off-patent branded and generic established medicines business comprising of six brands which included Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin along with related business assets and liabilities of Upjohn Business as a going concern to Mylan for a consideration of Rs 180.48 Crore. As a result, the Company transferred Upjohn business along with related business assets and liabilities to Mylan effective August 1, 2022. During the year 2022-23, the Company transferred its said Business Undertaking at Thane including the land, plant and machinery and all workmen employed to Vidhi Research & Development LLP effective February 24, 2023. In FY 2023-24, Company launched Betrecep (Tofacitinib) in July, 2023 for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Ulcerative Colitis. Becosules Syrup and Gelusil Raft preparation was launched in February, 2024. In August 2025, Company launched Prevenar 20. Emblaveo and Nurtec vaccines launched in FY26. Strategic partnerships with Cipla Limited and GoApptiv expanded market reach and patient access. Nurtec ODT (orally disintegrating tablet) was launched for the acute treatment of migraine in 2026.

    Fundamentals

    Financial strength and ownership structure

    Valuation & Ratios

    Market Capitalisation

    ₹1,394.87

    Price to Book (PB)

    -

    Price to Earnings (PE)

    -

    Return on Equity (ROE)

    19.78%

    Earnings Per Share (EPS)

    98.27

    Dividend Yield

    2.67%

    Financial Performance

    Shareholding Pattern

    63.92%
    63.92%
    63.92%
    63.92%
    Dec
    '25
    Mar
    '26
    Jun
    '26
    Sep
    '26